Article
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
All News
Article
Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
Article
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.
Dr. John Cush
Tweet
Retrospective study of 75 knee OA pts w/ SF aspiration and MRI showed Median SF WBC =284, w/ higher SF WBC w/medium/large effusions. Despite this trend, SF WBC did not strongly correlate w/ MRI inflammation (effusions or synovitis) https://t.co/6suIGJNLdW https://t.co/gNd1Dai4SI
Dr. John Cush
Tweet
Increasing Risk of Lupus Nephritis
A population based study shows that LN in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates 6x that of the general population.
https://t.co/iQ00MnFe2N https://t.co/3z9UrccdM1
Dr. John Cush
Tweet
PSOAS study of 354 with long-standing ankylosing spondylitis & SI radiographic changes; but 23 lacked syndesmophytes. Lack of fusion was more likely in women & w/younger age of Sx onset. All were B27+, thus B27 may be assoc w/ SI dz, not spinal dz. https://t.co/EpDW6wTZNr https://t.co/IHRvdkDiaD
Dr. John Cush
Tweet
Listen to the FDA Drug Safety Podcast (for HCPs). On the Risk of Serious Adverse events with JAK Inhibitors (based on their HCP safety alert from 9/21/2021). 4 min long, basic info, not alot of depth...but its from the FDA. https://t.co/0Hns5bDU2A https://t.co/mRKi8NEKGW
Dr. John Cush
Tweet
Pre and post-COVID-19 assessment of 78 FM pts by Fibromyalgia Impact Questionnaire-Revised (FIQR). While COVID affected FM pts, there was no statistically significant change in FIQR scores (65% had no improvement or deterioration on FIQR) https://t.co/S1clBCvzWm https://t.co/ZApmgvKM2c
Dr. John Cush
Tweet
2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis
Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).
https://t.co/oX8oXm0adU https://t.co/JyzT6VxMSQ
Dr. John Cush
Tweet
TNF inhibitors Dont Increase Cancer Risk! 4592 RA pts:TNFi Rx (2296) vs matched DMARD Rx (2296) pts. TNFi had a lower cancer risk than DMARD Rx (IR 6.5 vs. 15.6 /1000PYs]). TNFi had Lower HR GI CA (0.432), breast CA (0.146), GU CA (0.220) https://t.co/F5ToHLJULn
Dr. John Cush
Tweet
Mayo Clinic Biobank matched case-control study (1:3) of 212 incident RA cases Active work physical activity lowered risk of RA (aOR 3.00), while 3-5 servings high-fat foods, fruits/vegetables lowered risk (OR 0.45; OR 0.54). https://t.co/AAQ1nRfJXq https://t.co/72yLQUllDV
Dr. John Cush
Tweet
1915 Rheumatic (RMD)pts w/ COVID (42% RA. 15% SLE, 1/2 comorbidities); Outcomes: 28% hospitalized, 8% to ICU & 4% died from COVID-19. Poor COVID-19 outcomes seen w/ age, male, Hi Dz activity, steroids & RTX, & 1+ comorbidity https://t.co/ztBiJc9nxV https://t.co/RVOKyjseFJ
Dr. John Cush
Tweet
Acute Hot Joint? A systematic review of 49 articles, looking at SF & serum markers to distinguish septic vs non-septic joints. They found 8 discriminatory SF tests w/ WBC esterase highest sensitivity (0.94)& specificity (0.74) https://t.co/SamgBwyBrL https://t.co/t9JOiRMMHI
Dr. John Cush
Tweet
#Gout clinic study of 223 gout pts on allopurinol ≥300 mg compared Pt & MD gout control assessments (0-10). Better agreement & higher scores seen w/o flares (3 or 12 mos) & SUA w/in target. Disagreement (22%) w/ recent flares & tophi https://t.co/a0WsMLvfYk https://t.co/zZwV4XVJzS
Dr. John Cush
Tweet
Metanalysis of emergency department Rx of opioids for MSK pain - 42 articles, 6128 pts - Short term (2hr) benefits of ED opioids were statistically but not clinically more effective than PBO or Tylenol, but not better than NSAIDs. Safety uncertain. https://t.co/Lmf8Ubuacw https://t.co/prP6Ei3wqA
Dr. John Cush
Tweet
Will we see you there? #ACR2022
What are you most looking forward to on the agenda? https://t.co/6nUMBmqnTy
Dr. John Cush
Tweet
Predictors of serious infection (SIE) in SLE? A prior SIE conferred the highest risk of subsequent SIE. Study of 346 SLE pts shows SIE rate of 3.8/100 Pt-Yrs. Other risk factors:
Damage accrual, comorbidity, Dz activity, CTX use https://t.co/t65XzmFzQG https://t.co/78jiUnaq7d
Dr. John Cush
Tweet
Love the RheumNow podcast? Subscribe, rate and review!
Listen in the car, airplane, anywhere! We also reach more listeners through reviews from our users. Consider leaving a review!
https://t.co/QlcUIxqY8A https://t.co/k2ybeeYGz5
Dr. John Cush
Tweet
Pregnancy Outcomes with Belimumab
A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.
https://t.co/kybCgu3Rlp https://t.co/ckshcgDZbD
Dr. John Cush
Tweet
FDA has approves RINVOQ (upadacitinib) for the treatment of Active Non-Radiographic Axial Spondyloarthritis https://t.co/0HexNAJbtw https://t.co/agSzUVaXSF
